These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

960 related articles for article (PubMed ID: 19528466)

  • 1. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.
    Hegele A; Dalpke A; Barth P; Varga Z; Heeg K; Hofmann R; Olbert P
    Anticancer Res; 2004; 24(4):2225-30. PubMed ID: 15330165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunostimulatory CpG oligodeoxynucleotides (CpG-ODN) in an orthotopic murine transitional cell carcinoma (TCC) model. Effect on local cytokine expression].
    Olbert PJ; Schrader AJ; Hofmann R; Hegele A
    Urologe A; 2008 Sep; 47(9):1133-4, 1136. PubMed ID: 18679650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides.
    Hussain I; Jain VV; Kitagaki K; Businga TR; O'Shaughnessy P; Kline JN
    Laryngoscope; 2002 Oct; 112(10):1819-26. PubMed ID: 12368622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
    Wu Q; Mahendran R; Esuvaranathan K
    Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model.
    Hegele A; Dalpke A; Heeg K; Barth P; Varga Z; Hofmann R; Olbert P
    Tumour Biol; 2005; 26(5):274-80. PubMed ID: 16103747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
    De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
    J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A study on the mechanisms of mycobacterial clearance induced by CpG-oligodeoxynucleotides in mice].
    Ren T; Liang YJ; Cai YY; Li CY; Mei J; Yuan ZH; Tao MF; Tian M; Zhao B
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jan; 31(1):46-50. PubMed ID: 18366907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.
    Ninalga C; Loskog A; Klevenfeldt M; Essand M; Tötterman TH
    J Immunother; 2005; 28(1):20-7. PubMed ID: 15614041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma.
    Zhang G; Cao Y; Xu Y; See WA
    Urol Oncol; 2005; 23(6):413-8. PubMed ID: 16301119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
    Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
    J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release.
    Hong Z; Jiang Z; Liangxi W; Guofu D; Ping L; Yongling L; Wendong P; Minghai W
    Int Immunopharmacol; 2004 Feb; 4(2):223-34. PubMed ID: 14996414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CpG-ODN instillation boosts ICAM-1 expression in an orthotopic murine UCC model: immunohistochemical evaluation of the local response to immunostimulatory DNA].
    Klebe M; Olbert PJ; Hofmann R; Barth PJ; Hegele A
    Aktuelle Urol; 2024 Apr; 55(2):154-160. PubMed ID: 33853160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction.
    Bleich A; Janus LM; Smoczek A; Westendorf AM; Strauch U; Mähler M; Hedrich HJ; Fichtner-Feigl S; Schölmerich J; Falk W; Hofmann C; Obermeier F
    Gastroenterology; 2009 Jan; 136(1):278-87. PubMed ID: 18952084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder.
    O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
    J Urol; 2004 Mar; 171(3):1336-42. PubMed ID: 14767344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local therapy with CpG motifs in a murine model of allergic airway inflammation in IFN-beta knock-out mice.
    Matheu V; Treschow A; Teige I; Navikas V; Issazadeh-Navikas S
    Respir Res; 2005 Mar; 6(1):25. PubMed ID: 15748290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
    Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
    Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.